Precision medicine approach for heart failure management
Heart Failure Precision Medicine Study
This study is testing a new way to personalize heart failure treatment by using advanced technology to better understand each patient's unique condition and improve their care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Trial ID | NCT04196842 on ClinicalTrials.gov |
What this trial studies
This study investigates how multi-omics profiling can identify specific heart failure profiles that are at risk for adverse outcomes. It aims to integrate clinical data with molecular information to enhance understanding of heart failure and improve treatment strategies. The study will recruit 1000 participants and utilize telemonitoring devices to optimize guideline-directed medical therapy. By employing longitudinal phenomapping and high-throughput molecular approaches, the study seeks to provide a comprehensive view of heart failure pathophysiology and treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with heart failure who have objective evidence of cardiac abnormalities and are in stages B-D and classes I-IV.
Not a fit: Patients unable to consent, those with significant comorbidities, or those who cannot comply with the study protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with heart failure.
How similar studies have performed: Other studies utilizing multi-omics and precision medicine approaches have shown promise in improving outcomes for heart failure patients, indicating a potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Heart failure * Objective evidence of cardiac abnormality of structure or function (abnormal ECHO) or elevated levels of B-type natriuretic peptide (\>100 pg/ml) * HF stage B-D and class I-IV Exclusion Criteria: * Patients unable to consent * Inability to comply with the protocol and follow-up requirements * Patients unable to use a smartphone * Patients assessed irregularly (less than two visits in one year) * History of HTx * Use of Mechanical circulatory support device (MCSD) * Comorbidities that, according to the PI, have the potential to interfere with the interpretation of the results
Where this trial is running
Sacramento, California
- UC Davis Medical Center — Sacramento, California, United States (Recruiting)
Study contacts
- Principal investigator: Martin Cadeiras, MD — University of California, Davis
- Study coordinator: Erick S Romero, MD
- Email: esromero@ucdavis.edu
- Phone: (916) 703-2071
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.